CM
MRSN

Caption Management’s Mersana Therapeutics MRSN Stock Holding History

Caption Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-408
Closed -$19.3K – 1696
2024
Q3 		$19.3K Hold
408
– – ﹤0.01% 1206
2024
Q2 		$20.5K Buy
+408
New +$29.5K ﹤0.01% 1084
2023
Q3 		– Sell
-7,240
Closed -$595K – 1427
2023
Q2 		$595K Sell
7,240
-4,596
-39% -$672K 0.01% 784
2023
Q1 		$1.22M Buy
+11,836
New +$1.66M 0.02% 585
2021
Q3 		– Sell
-2,188
Closed -$742K – 1682
2021
Q2 		$742K Sell
2,188
-7,658
-78% -$2.9M 0.01% 962
2021
Q1 		$3.98M Buy
+9,846
New +$4.78M 0.09% 307

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Caption Management's MRSN Position: Q4 2024 in Review

Caption Management sold out of Mersana Therapeutics (MRSN) in Q4 2024, closing a stake of 408 shares — an estimated $19.3K sold.

Caption Management first reported a position in MRSN in Q1 2021 and held it in 6 quarters. The position peaked at $3.98M in Q1 2021. 128 funds tracked by Wall St. Rank hold MRSN as of Q4 2024.

  • Caption Management reported no remaining Mersana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Caption Management sold 408 Mersana Therapeutics shares in Q4 2024, an estimated $19.3K.
  • Caption Management first reported a position in Mersana Therapeutics in Q1 2021 and held it in 6 quarters.
  • Caption Management's Mersana Therapeutics position peaked at $3.98M in Q1 2021.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2024.

Based on Caption Management's 13F filing for Q4 2024, filed 14 Feb 2025.